Stock listing
Frankfurt:5JD0 ExpreS2ion Biotech Holding AB Aktie
German listing (Frankfurt) of ExpreS2ion Biotech Holding AB · home listing Stockholm:EXPRS2
Follow ExpreS2ion Biotech Holding AB into a list and get an email when it puts out news.
Share price · FWB:5JD0
€0.055 EUR -0.004 (-6.4%)
Close on Oct 30, 2026
- Day range
- €0.055 – €0.055 EUROct 30, 2026
- Market cap
- €545,557 EURAt the close on Oct 30, 2026 · price × 9.88M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:EXPRS2 · Home | 0.992 SEK | +0.058 (+6.2%) | 64,529 | 0.936 | 1.000 | 0.900 | 0.934 | Close on Nov 2, 2026 |
| Frankfurt:5JD0 | €0.055 EUR | -0.004 (-6.4%) | — | €0.055 | €0.055 | €0.055 | €0.059 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:5JD0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 14, 2026
ExpreS2ion Biotech Obtains Commitment for Warrant Program TO 13 and enters into SEK 50 Million Put Option Agreement with lead investor Alumni Capital
Latest earnings call · Aug 20, 2026
Expres2ion Biotech Holding (Stockholm:EXPRS2) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 7, 2026
Investor Presentation (October 2026)
Investor deck · 9 slides
Calls
Replays
Expres2ion Biotech Holding (Stockholm:EXPRS2) Q2 2026 Earnings Call
Thu, Aug 20, 2026 · 4:00 AM ET
Watch TranscriptExpres2ion Biotech Holding (Stockholm:EXPRS2) Q1 2026 Earnings Call
Thu, May 28, 2026 · 4:00 AM ET
Watch TranscriptExpres2ion Biotech Holding (Stockholm:EXPRS2) Q4 2025 Earnings Call
Thu, Feb 19, 2026 · 3:00 AM ET
Watch Transcript
Latest news
Financings
New shares on exercise of TO 13 warrants and directed issue to guarantor
Sep 14, 2026 · US$1.98M
Announced: SEK 19.3M–SEK 32.4M · SEK 1.6 a share · Vator Securities +2
Dealers: Vator Securities, SCHMIDT Capital Advisors, APREA Partners
Buyers: Vator Securities (guarantee undertaking totalling SEK 19.3 million); Alumni Capital; Tellus Equity AB; Leif Helth Jensen; John Haurum; Thomas Larsson
Use of proceeds: Complete the ES2B-C001 Phase I study, strengthen licensing negotiations, platform and CMC development, and business development
New shares under put option agreement
Sep 14, 2026 · US$5.12M
Announced: up to SEK 50M
Buyers: Alumni Capital Limited (commitment of up to SEK 50,000,000 in equity financing over 24 months)
Decks
Investor Presentation (October 2026)
Investor deck · 9 slides · Oct 7, 2026
Q2 2026 Earnings Presentation
Earnings · 23 slides · Aug 20, 2026
Q1 2026 Earnings Presentation
Earnings · 21 slides · May 28, 2026
Q1 2026 Earnings Presentation
Earnings · 24 slides · May 28, 2026
ExpreS2ion Biotech Holding AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 12 in all · newest Sep 14, 2026 · oldest 2026
- Calls
- 10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
- Decks
- 52 decks · latest Oct 7, 2026
Where ExpreS2ion Biotech Holding AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:EXPRS2 · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A40P4H | LS Exchange | Germany | EUR |
| Lang & Schwarz:A40P4H | Lang & Schwarz | Germany | EUR |
| gettex:5JD0 | gettex | Germany | EUR |
| Stuttgart:5JD0 | Stuttgart | Germany | EUR |
| Frankfurt:5JD0 · This page | Frankfurt | Germany | EUR |
| Munich:5JD0 | Munich | Germany | EUR |
Log in to ask 6ix AI your own questions about ExpreS2ion Biotech Holding AB.